Company news
Kymera Therapeutics, Inc. news in 2020
Kymera Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Kymera Therapeutics Announces Key Leadership Appointments
December 15, 2020
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
December 6, 2020
Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference
November 22, 2020
Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 10, 2020
Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
November 4, 2020
Kymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
November 3, 2020
Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit
October 11, 2020
Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa
October 8, 2020
Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
September 13, 2020
Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors
September 8, 2020
Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer
August 26, 2020
Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
August 24, 2020
Decks in 2020
- Technical Presentation (December 2020)
Technical · 9 slides · December 2020